ArticleOncotarget2015

A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.

Eva-Maria Nichols et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.